Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report)'s stock price was up 6.2% on Friday . The stock traded as high as $9.40 and last traded at $9.61. Approximately 232,015 shares changed hands during trading, a decline of 87% from the average daily volume of 1,852,676 shares. The stock had previously closed at $9.05.
Wall Street Analyst Weigh In
PHAT has been the topic of a number of research analyst reports. HC Wainwright reissued a "buy" rating and issued a $20.00 price target on shares of Phathom Pharmaceuticals in a research note on Monday, June 9th. Needham & Company LLC reissued a "buy" rating and issued a $28.00 price target on shares of Phathom Pharmaceuticals in a research note on Friday, June 6th. Craig Hallum lifted their price target on shares of Phathom Pharmaceuticals from $12.00 to $17.00 and gave the company a "buy" rating in a research note on Monday, June 9th. The Goldman Sachs Group dropped their price target on shares of Phathom Pharmaceuticals from $10.00 to $5.00 and set a "neutral" rating on the stock in a research note on Friday, May 2nd. Finally, Guggenheim dropped their price target on shares of Phathom Pharmaceuticals from $18.00 to $12.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $17.50.
View Our Latest Report on Phathom Pharmaceuticals
Phathom Pharmaceuticals Stock Performance
The firm's 50 day simple moving average is $7.98 and its 200-day simple moving average is $6.15. The company has a market cap of $601.80 million, a price-to-earnings ratio of -1.65 and a beta of 0.45.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC raised its holdings in shares of Phathom Pharmaceuticals by 797.2% during the 1st quarter. GAMMA Investing LLC now owns 4,558 shares of the company's stock worth $29,000 after acquiring an additional 4,050 shares during the period. CWM LLC raised its holdings in shares of Phathom Pharmaceuticals by 20,997.1% during the 1st quarter. CWM LLC now owns 7,384 shares of the company's stock worth $46,000 after acquiring an additional 7,349 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of Phathom Pharmaceuticals during the 4th quarter worth $74,000. Teacher Retirement System of Texas purchased a new position in shares of Phathom Pharmaceuticals during the 4th quarter worth $90,000. Finally, Rafferty Asset Management LLC purchased a new position in shares of Phathom Pharmaceuticals during the 4th quarter worth $90,000. Hedge funds and other institutional investors own 99.01% of the company's stock.
Phathom Pharmaceuticals Company Profile
(
Get Free Report)
Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
Read More
Before you consider Phathom Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phathom Pharmaceuticals wasn't on the list.
While Phathom Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.